ClinicalTrials.gg
RecruitingNCT06939686STRIDDDEUpdated Dec 24, 2025

Miro3D Wound Matrix Study for Diabetic Foot Ulcers and Wound Healing

An interventional study of Miro3D Wound Matrix and Standard of Care (SOC) in Diabetic Foot Ulcers (DFUs) and Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer), sponsored by Reprise Biomedical, Inc.. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by Reprise Biomedical, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Nov 2024, registered Apr 2025).
  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 381 studies in Diabetic Foot with a site in United States — 66 open to participants now, 84 under way, 3 of them phase 3. Diabetic Foot · United States.

Planned enrollment
214th of 322
30 · median 60
Started
2024
with 32 others
No phase
186 of 381
38 open now
Primary completion
2026-07
later than 30 of 83 live
Registered
344th of 381
by date

Among the 381 studies in Diabetic Foot with a site in United States, this one is the 214th largest by planned enrollment of the 322 interventional ones that give a count, is one of 33 that started in 2024, is one of 186 with no phase, reaches primary completion later than 30 of the 83 other live ones, and was the 344th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

66 of the 381 studies in Diabetic Foot with a site in United States are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies in Diabetic Foot with a site in United States, or all of them as a file.
02

Study summary

This study is a prospective, randomized controlled trial designed to evaluate the effectiveness of Miro3D Wound Matrix plus Standard of Care (SOC) compared to SOC alone in treating Wagner Grade 1 diabetic foot ulcers (DFUs) and wound dehiscence in an outpatient setting. The trial is sponsored by Reprise Biomedical, Inc. and aims to explore whether the addition of Miro3D-a three-dimensional, acellular porcine-derived wound matrix-enhances wound healing outcomes compared to SOC alone.

Purpose of the Study: The primary purpose of the study is to determine whether applying Miro3D in combination with SOC leads to improved healing of diabetic foot ulcers compared to SOC alone. Specifically, the study seeks to assess early wound healing progress at four weeks (as measured by percent area reduction and granulation tissue formation) as a predictor of complete healing by twelve weeks.

Key Question the Study Seeks to Answer: Does the addition of Miro3D to standard wound care improve the healing rate and overall wound outcomes for patients with Wagner Grade 1 diabetic foot ulcers or dehisced wounds compared to standard care alone?

Study Design Overview: Subjects who meet inclusion/exclusion criteria will be randomized into one of two groups:

  1. Miro3D + SOC arm - receiving Miro3D weekly for 4 weeks, then biweekly if needed, for up to 12 weeks.
  2. SOC alone (control) arm - receiving SOC without Miro3D. If the wound remains unhealed at 12 weeks in the SOC alone arm, participants may "crossover" to receive Miro3D treatment under the same schedule for an additional 12 weeks.

Primary Endpoint:

1. Percent Area Reduction (PAR) and granulation tissue formation at 4 weeks, serving as predictors for wound healing at 12 weeks.

Secondary Endpoints:

  1. Quality of Life (QOL) improvements, including pain, mobility, and emotional well-being, assessed using a validated Wound/Ulcer-QOL tool.
  2. Pain levels using a Visual Analog Scale (VAS) at each visit.

Population: Approximately 30 adult subjects (15 per arm) with Wagner Grade 1 diabetic foot ulcers or dehisced wounds will be enrolled. Subjects must have adequate blood flow, demonstrate wound size criteria, and commit to offloading and follow-up care.

Follow-Up: Subjects will be followed weekly through the 12-week study period. Healed subjects will undergo confirmation visits at 2 and 4 weeks post-closure. Subjects in the crossover arm will be followed for an additional 12 weeks if their wound was unhealed at the primary endpoint.

Statistical Considerations: Data will be summarized using descriptive statistics, including wound measurements, infection status, and healing rates. Comparative analysis will be conducted between treatment groups and schedules (weekly vs. biweekly Miro3D application). Adverse events (AEs), serious adverse events (SAEs), and device-related events will also be documented.

This study aims to generate clinical evidence supporting the use of Miro3D as a beneficial adjunct to standard wound care in promoting early and complete healing of diabetic foot ulcers.

Read the detailed description

This prospective, randomized controlled trial evaluates the clinical effectiveness of Reprise Biomedical's Miro3D Wound Matrix in conjunction with standard of care (SOC) compared to SOC alone in treating Wagner Grade 1 diabetic foot ulcers (DFUs) in an outpatient setting. The investigational product, Miro3D, is a porcine liver-derived, acellular, three-dimensional extracellular matrix designed to support healing in complex wound environments by providing a biologically active scaffold that facilitates cell infiltration and tissue remodeling. This study aims to generate robust clinical evidence supporting Miro3D's role as an advanced biologic dressing for early and sustained wound healing in diabetic patients.

Background and Rationale: Diabetic foot ulcers are a common and serious complication of diabetes mellitus, affecting approximately 15-25% of individuals with diabetes over their lifetime. These ulcers are associated with high morbidity, increased healthcare utilization, and significant risk of lower extremity amputation. Despite established guidelines, many DFUs fail to heal adequately with standard of care alone, especially when early progress is not observed. According to consensus recommendations, wounds that do not demonstrate at least a 50% reduction in area within the first four weeks of SOC are unlikely to achieve closure by 12 weeks and are considered candidates for advanced wound therapies.

Advanced biologic matrices aim to address the limitations of SOC by enhancing the local wound environment. Miro3D is a perfusion-decellularized extracellular matrix derived from porcine liver, preserving native microvascular architecture and providing a highly porous scaffold for cellular infiltration. Unlike many sheet-based dermal matrices, Miro3D possesses significant three-dimensional structure and volume, making it suitable for filling shallow to moderately deep wound beds. The device is supplied sterile and dry, rehydrated at the point of care, trimmed to fit, and applied directly to the wound bed.

This study is designed to evaluate whether the addition of Miro3D to SOC accelerates healing and improves outcomes in Wagner Grade 1 DFUs, a common clinical presentation that often remains refractory to SOC alone. The trial also includes a crossover design for non-responders in the SOC arm, enhancing ethical treatment access while generating additional observational data.

Device Description and Mechanism of Action: Miro3D Wound Matrix is a sterile, acellular scaffold composed of porcine-derived extracellular matrix processed via perfusion decellularization to retain native liver architecture. The matrix is characterized by high porosity, preserved vascular pathways, and structural integrity, supporting rapid integration into the wound bed. Once rehydrated, Miro3D becomes pliable and conformable, suitable for application to irregular wound geometries.

Mechanistically, Miro3D provides a physical and biochemical scaffold that promotes cell adhesion, migration, angiogenesis, and granulation. As a non-crosslinked, resorbable collagen matrix, it undergoes host remodeling over time, integrating into newly formed tissue. The device can be trimmed to wound dimensions and applied weekly or biweekly depending on healing progression.

Study Objectives and Hypothesis: The primary objective of the study is to determine whether the application of Miro3D in combination with SOC leads to superior healing outcomes compared to SOC alone in the treatment of Wagner Grade 1 DFUs.

Primary Hypothesis: Miro3D + SOC will result in a significantly higher proportion of wounds achieving ≥50% area reduction and robust granulation tissue formation at 4 weeks, predictive of complete closure by 12 weeks.

Secondary Hypotheses: Subjects treated with Miro3D + SOC will demonstrate faster time to healing, improved patient-reported quality of life (QOL), reduced pain, and comparable or improved safety compared to those receiving SOC alone.

Study Design and Randomization: This is a randomized controlled trial enrolling approximately 30 subjects (15 per arm). Subjects meeting eligibility criteria will be randomized in a 1:1 ratio to either:

  1. Intervention Arm (Miro3D + SOC): Weekly Miro3D application for the first four weeks, followed by biweekly application if the wound remains unhealed, for up to 12 weeks.
  2. Control Arm (SOC alone): Standard wound care practices without Miro3D. Subjects with unhealed wounds at 12 weeks are eligible to cross over to receive Miro3D under the same application schedule for an additional 12-week observational phase.

Randomization will use sealed envelope assignment to ensure unbiased group assignment.

Visit Schedule and Study Assessments:

  1. Screening Visit (Week -2 to 0):

    • Informed consent
    • Wound debridement and imaging
    • Vascular assessment
    • HbA1c testing, pregnancy test if applicable
    • Run-in period
  2. Randomization Visit (Week 0):

    • Confirm eligibility
    • Randomization
    • Baseline wound measurements and photos
    • QOL and pain scale assessments
    • First application of Miro3D (intervention arm)
  3. Weekly Treatment Visits (Weeks 1-11):

    • Wound imaging and measurements
    • Clinical assessment and re-debridement as needed
    • Miro3D reapplication (as indicated)
    • Pain assessment and adverse event tracking
  4. End-of-Treatment Visit (Week 12):

    • Final wound assessment
    • Confirmation of wound closure
    • Final QOL and pain scale assessments
    • Eligibility for crossover (control arm, if unhealed)
  5. Crossover Phase (Weeks 13-24, as needed):

    • Subjects from SOC arm receive Miro3D + SOC
    • Follow-up per the intervention arm protocol
  6. Closure Confirmation Visits (2 and 4 weeks post-closure):

    • Validation of sustained healing

Crossover Design and Follow-Up: Subjects in the SOC arm who do not achieve complete healing by Week 12 are eligible to cross over to receive Miro3D under the same application schedule. The crossover phase is observational and not included in the primary efficacy analysis. These data will help characterize Miro3D's performance as a rescue therapy in chronic wounds unresponsive to SOC.

Subjects who achieve healing during the randomized phase or crossover phase will undergo 2- and 4-week confirmation visits to validate sustained closure.

Safety Monitoring and Adverse Event Reporting: All adverse events will be documented, assessed for severity and relatedness, and reported per FDA and IRB requirements. Investigators will monitor subjects for infection, delayed healing, inflammatory reactions, and systemic complications. Device-related events will be tracked by lot number.

Unanticipated adverse device effects (UADEs), if any, will be escalated to the sponsor and appropriate regulatory bodies. Based on previous clinical use of hepatic-derived ECM scaffolds, Miro3D is expected to demonstrate a favorable safety profile.

Regulatory, Ethical, and Clinical Context: Miro3D Wound Matrix is FDA-cleared under 510(k) as a Class II medical device (K223257) for use in managing partial- and full-thickness wounds. This trial is conducted as a post-market, investigator-initiated study in accordance with Good Clinical Practice (GCP), IRB approval, and informed consent regulations under 21 CFR Part 50.

The trial addresses a critical gap in clinical evidence by comparing Miro3D to SOC in a randomized, controlled framework. Few biologic wound matrices have RCT-level data supporting early use in Wagner Grade 1 DFUs. The findings will inform clinical guidelines, payer coverage decisions, and the design of larger-scale trials aimed at improving outcomes for patients with chronic diabetic wounds.

03

Conditions studied

  • Diabetic Foot Ulcers (DFUs)
  • Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer)

Keywords

  • Diabetic Foot Ulcer
  • Chronic Wound Healing
  • Miro3D Wound Matrix
  • Acellular Wound Scaffold
  • Porcine-derived Wound Matrix
  • Biologic Wound Matrix
  • Wound Granulation
  • Percentage Area Reduction
  • Reprise Biomedical
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be at least 18 years of age and capable of providing .
  2. Must have a full- or partial-thickness Wagner Grade 1 ulcer or wound on the foot; if involving the malleolus, no more than 50% of the wound may be above the midpoint of the medial malleolus.
  3. Index wound/ulcer must be between 1 cm² and 20 cm² post-debridement.
  4. Wound/ulcer must have been present for at least 4 weeks prior to screening.
  5. Adequate circulation must be documented by one of the following: ABI between 0.7-1.2, TBI ≥ 0.7, TCPO2 ≥ 40 mmHg, or triphasic/biphasic Doppler waveforms.
  6. Other wounds, if present, must be at least 2 cm from the index wound/ulcer.
  7. Any previous infections must have been adequately treated per IDSA guidelines.
  8. Subjects must agree to proper offloading and/or compression, have a stable living environment, and be able to attend follow-up visits.
  9. Must provide written consent for digital imaging.
  10. For Miro3D arm: Index wound/ulcer must have a clean base free of devitalized tissue or debris at the time of product placement.

Exclusion criteria

Exclusion Criteria:

  1. Index wound/ulcer has reduced ≥30% after two weeks of SOC from screening to baseline.
  2. Poorly controlled diabetes ( ≥ 12%).
  3. Active, untreated or uncontrolled osteomyelitis.
  4. or vasculitis at the wound site.
  5. Undergoing chemotherapy.
  6. On dialysis.
  7. Use of drugs or therapies within 30 days prior to screening.
  8. Conditions that would compromise study participation or adherence.
  9. Known sensitivity to porcine materials.
  10. Third-degree burns.
  11. Worsening ischemia or gangrene at screening.
  12. History of radiation to the wound site.
  13. Exposed internal fixation, implants, or hardware in the wound.
  14. Patient is transitioning to palliative or comfort care.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Miro3D Wound Matrix plus Standard of Care (SOC)

    Subjects randomized to this arm receive Miro3D Wound Matrix in combination with standard of care wound treatment. * Miro3D is applied once every 7 days for the first 4 weeks. * If the wound is not healed after 4 weeks, Miro3D is applied biweekly (every 14 days) through week 12 or until healing. * All subjects in this arm are assessed weekly for healing progress, wound measurements, granulation, pain (VAS), and QOL.

    Device: Miro3D Wound Matrix · Other: Standard of Care (SOC)

  • Active comparator
    Standard of Care (SOC) Alone

    Subjects in this arm receive standard wound care without Miro3D, including wound cleaning, debridement, offloading, and appropriate dressings. * Healing progress is evaluated weekly over the 12-week treatment period. * Subjects whose wounds remain unhealed at week 12 may elect to crossover to Miro3D treatment, following the same protocol used in Arm 1.

    Other: Standard of Care (SOC)

Interventions

  • DeviceMiro3D Wound Matrix

    Miro3D is a sterile, acellular, three-dimensional biologic wound matrix derived from porcine liver via perfusion decellularization and drying. It is trimmed to fit the wound and rehydrated with sterile saline or Lactated Ringer's solution before application. It provides a porous scaffold to support granulation and healing in chronic or post-surgical wounds.

    Also known as: Miro3D

  • OtherStandard of Care (SOC)

    SOC includes standard wound care practices such as wound cleansing, debridement, infection management (if applicable), use of protective dressings (e.g., Aquacel or foam covered with Adaptic), and offloading devices (e.g., Foot Defender boot) to relieve pressure on the wound.

    Also known as: SOC

06

What researchers measure

Primary outcomes

  1. Percent Area Reduction (PAR) and Granulation Tissue Formation at 4 Weeks

    The primary endpoint is the percent area reduction (PAR) and granulation tissue formation of the index wound or ulcer measured at 4 weeks. This serves as a predictor of complete healing by week 12. Wound size is measured manually using a ruler, and depth is assessed with a probe. Granulation is visually assessed by trained clinicians.

    Time frame: 4 weeks post-randomization

Secondary outcomes

  1. Complete Wound or Ulcer Healing by Week 12

    The proportion of subjects whose index wound or ulcer is fully healed (defined as full epithelialization without drainage) at or before week 12. Closure must be sustained for 4 consecutive weeks and confirmed by follow-up visits.

    Time frame: Up to 12 weeks post-randomization

  2. Quality of Life (QOL) Assessment Using Wound-QOL Instrument

    Change from baseline in subject-reported quality of life using the Wound-QOL tool, which assesses domains such as pain, odor, physical function, mobility, depression, and social isolation.

    Time frame: Baseline, Week 4, Week 8, and Week 12 or at early termination

  3. Pain Score Assessment Using Visual Analog Scale (VAS)

    Change from baseline in pain intensity as measured by a standard 0-10 Visual Analog Scale (VAS), where 0 represents no pain and 10 represents worst possible pain.

    Time frame: Collected at every study visit (weekly through week 12)

Other outcomes

  1. Healing Trajectory at Weeks 6 and 8

    Interim assessments of percent area reduction (PAR) and granulation at weeks 6 and 8 to evaluate healing trajectory and likelihood of closure by week 12.

    Time frame: 6 weeks and 8 weeks post-randomization

  2. Safety Profile: Adverse Events (AEs), Serious Adverse Events (SAEs), and Unanticipated Adverse Device Effects (UADEs)

    Collection and evaluation of all adverse events, serious adverse events, and unanticipated adverse device effects. Events will be assessed for severity, expectedness, and relationship to the study device or SOC.

    Time frame: From informed consent through 30 days post-final study visit

07

Study locations

1 of 3 sites recruiting
08

References and documents

Publications

  • Warriner RA, Snyder RJ, Cardinal MH. Differentiating diabetic foot ulcers that are unlikely to heal by 12 weeks following achieving 50% percent area reduction at 4 weeks. Int Wound J. 2011 Dec;8(6):632-7. doi: 10.1111/j.1742-481X.2011.00860.x. Epub 2011 Sep 23. PubMed 21951763 ↗
  • Snyder RJ, Cardinal M, Dauphinee DM, Stavosky J. A post-hoc analysis of reduction in diabetic foot ulcer size at 4 weeks as a predictor of healing by 12 weeks. Ostomy Wound Manage. 2010 Mar 1;56(3):44-50. PubMed 20368673 ↗
  • Smith ME, Totten A, Hickam DH, Fu R, Wasson N, Rahman B, Motu'apuaka M, Saha S. Pressure ulcer treatment strategies: a systematic comparative effectiveness review. Ann Intern Med. 2013 Jul 2;159(1):39-50. doi: 10.7326/0003-4819-159-1-201307020-00007. PubMed 23817703 ↗
  • Raghav A, Khan ZA, Labala RK, Ahmad J, Noor S, Mishra BK. Financial burden of diabetic foot ulcers to world: a progressive topic to discuss always. Ther Adv Endocrinol Metab. 2018 Jan;9(1):29-31. doi: 10.1177/2042018817744513. Epub 2017 Dec 12. PubMed 29344337 ↗
  • Padula WV, Delarmente BA. The national cost of hospital-acquired pressure injuries in the United States. Int Wound J. 2019 Jun;16(3):634-640. doi: 10.1111/iwj.13071. Epub 2019 Jan 28. PubMed 30693644 ↗
  • Mervis JS, Phillips TJ. Pressure ulcers: Pathophysiology, epidemiology, risk factors, and presentation. J Am Acad Dermatol. 2019 Oct;81(4):881-890. doi: 10.1016/j.jaad.2018.12.069. Epub 2019 Jan 18. PubMed 30664905 ↗
  • Kruger EA, Pires M, Ngann Y, Sterling M, Rubayi S. Comprehensive management of pressure ulcers in spinal cord injury: current concepts and future trends. J Spinal Cord Med. 2013 Nov;36(6):572-85. doi: 10.1179/2045772313Y.0000000093. Epub 2013 May 21. PubMed 24090179 ↗
  • Geriatric Medicine Gerontology Chapter 30 - Pressure Ulcers. (n.d.). Retrieved from Johns Hopkins: https://www.hopkinsmedicine.org/geriatric_medicine_gerontology/_downloads/readings/section8.pdf
  • Bauer K, Rock K, Nazzal M, Jones O, Qu W. Pressure Ulcers in the United States' Inpatient Population From 2008 to 2012: Results of a Retrospective Nationwide Study. Ostomy Wound Manage. 2016 Nov;62(11):30-38. PubMed 27861135 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jul 2026, 20 months after the start.

Of 104 industry-sponsored interventional studies with no phase under Diabetic Foot, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 20 months is below that.

Counting every sponsor, half of 347 studies reached it within 22 months; a quarter within 9 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2025
First posted
Apr 23, 2025
StartActual
Nov 1, 2024
Primary completionEst.
Jul 31, 2026
CompletionEst.
Jul 31, 2026
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06939686
Lead sponsor
Reprise Biomedical, Inc.
Collaborators
Barry University, Icahn School of Medicine at Mount Sinai
Responsible party
Sponsor
First posted
Apr 23, 2025
Start date
Nov 1, 2024
Primary completion
Jul 31, 2026 (estimated)
Completion
Jul 31, 2026 (estimated)
Last update
Dec 24, 2025

Study contacts

Maria Swartz
Contact
mswartz@barry.edu
954-721-4806
Robert J. Snyder, DPM
principal investigator · Barry University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion